In a filing, Harvard Bioscience Inc revealed its Chief Executive Officer Green James W acquired Company’s shares for reported $29100.0 on Jun 13 ’24. In the deal valued at $2.91 per share,10,000 shares were bought. As a result of this transaction, Green James W now holds 3,111,091 shares worth roughly $1.09 million.
Then, Green James W bought 20,000 shares, generating $61,400 in total proceeds. Upon buying the shares at $3.07, the Chief Executive Officer now owns 3,101,091 shares.
KeyBanc Capital Markets downgraded its Harvard Bioscience Inc [HBIO] rating to a Sector weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including The Benchmark Company’s analysts, who increased its forecast for the stock in early March from “a Speculative buy” to “a Buy”. The Benchmark Company also remained covering HBIO and has increased its forecast on January 07, 2021 with a “Buy” recommendation from previously “Speculative buy” rating. Northland Capital started covering the stock on December 09, 2020. It rated HBIO as “an Outperform”.
Price Performance Review of HBIO
On Monday, Harvard Bioscience Inc [NASDAQ:HBIO] saw its stock jump 11.78% to $0.35. Over the last five days, the stock has gained 6.73%. Harvard Bioscience Inc shares have fallen nearly -83.31% since the year began. Nevertheless, the stocks have fallen -90.43% over the past one year. While a 52-week high of $3.62 was reached on 01/06/25, a 52-week low of $0.29 was recorded on 05/07/25. SMA at 50 days reached $0.5146, while 200 days put it at $1.8564.
Levels Of Support And Resistance For HBIO Stock
The 24-hour chart illustrates a support level at 0.2186, which if violated will result in even more drops to 0.0851. On the upside, there is a resistance level at 0.5778. A further resistance level may holdings at 0.8035. The Relative Strength Index (RSI) on the 14-day chart is 38.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0235, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.66%. Stochastics %K at 15.31% indicates the stock is a buying.
The most recent change occurred on November 10, 2020 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $6 price target.
